SCHEMBL14827205

SCHEMBL14827205

Cc1cn(-c2ccccc2)c(C=O)cc1=O

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.47
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 2/20 0.42
CYP1A2 P05177 1/20 0.42
HPGD P15428 1/20 0.42
BLM P54132 1/20 0.42
HSD17B10 Q99714 1/20 0.42
COMT P21964 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.37
BRD4 O60885 1/20 0.37
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NQO2 P16083 1/20 0.34
P2RX7 Q99572 1/20 0.34
NAPRT Q6XQN6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13817620 0.81 ATM (0.52) ATMALDH1A1KDM4ECYP1A2HPGD
SCHEMBL14827200 0.79 COMT (0.54) ALDH1A1KDM4ECYP1A2HPGDBLM
SCHEMBL14827207 0.73 COMT (0.71) ALDH1A1KDM4ECYP1A2HPGDBLM
SCHEMBL14827193 0.73 COMT (0.50) ALDH1A1KDM4ECYP1A2HPGDBLM
SCHEMBL25294091 0.70 SMN1; SMN2 (0.47) ATMALDH1A1KDM4ECYP1A2HPGD
SCHEMBL5858717 0.70 ALDH1A1 (0.50) ATMALDH1A1KDM4ECYP1A2HPGD
SCHEMBL6900554 0.70 ALDH1A1 (0.47) ALDH1A1MEN1KMT2A
SCHEMBL16474750 0.69 KDM4E (0.58) ALDH1A1KDM4ECYP1A2HPGDBLM
SCHEMBL14827206 0.68 COMT (0.41) ALDH1A1KDM4ECYP1A2HPGDBLM
SCHEMBL14827223 0.68 COMT (0.74) ATMALDH1A1COMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9399651-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders Merck, Sharp & Dohme Corp. (US) 2016-07-26 US disclosed
US-20150299227-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2015-10-22 US disclosed
US-9024032-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders MERCK SHARP & DOHME CORP. (US) 2015-05-05 US disclosed
US-20130084346-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME LLC 2013-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299227-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT ATM 3987/4885ALDH1A1 186/4885KDM4E 671/4885
US-20130084346-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT ATM 3987/4885ALDH1A1 186/4885KDM4E 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.